Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPAM Systems Inc (EPAM) vs Revvity Inc (RVTY) Price & Performance

EPAM Systems IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

EPAM Systems Inc vs Revvity Inc — how do they compare? EPAM Systems Inc trades at $85.95 (market cap $4.49B), while Revvity Inc trades at $111.14 (market cap $12.42B). The key difference: Revvity Inc is far larger — about 2.8× EPAM Systems Inc's market cap, and Revvity Inc pays a 0.25% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.

EPAMRVTY
Market Cap
$4.49B$12.42B
Sector
TechnologyTechnology
52-Week High
$221.40$117.75
52-Week Low
$76.04$82.26
Enterprise Value
$3.74B$14.91B
Dividend Yield
0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPAM Systems Inc

EPAM Systems trades at $87.22, up 3.22% today, with strong analyst support (65% buy ratings) and a consensus price target of $128.55 suggesting 47% upside. The stock shows attractive valuation metrics with P/E of 12.35 and P/S of 0.86, though technical indicators signal bearish momentum. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $2.86 exceeding expectations by $0.11. The company maintains solid profitability with 6.96% net margin and 10.93% ROE.

EPAM presents a compelling value opportunity with significant upside potential based on analyst targets, though near-term technical weakness and recent index reclassification from S&P 500 to SmallCap 600 create headwinds. The company's AI transformation expertise and strong client partnerships position it for growth, but investors should monitor execution risks and competitive pressures in the IT services sector.

Revvity Inc

RVTY trades at $110.99, down slightly by 0.2% today, near the analyst consensus price target of $111.43. The stock shows a bullish technical trend with recent earnings beats in Q3 2025, Q4 2025, and Q1 2026. Strong profitability metrics include a gross margin of 54.32% and net income margin of 8.26%. Recent news highlights AI integration advancements and FDA clearances, supporting growth prospects.

The outlook is positive with analyst consensus leaning buy (51.72%) and no sell ratings. Key risks include margin pressure and macroeconomic headwinds affecting cash flow, which turned negative in 2025 and 2026. The upcoming Q2 2026 earnings report on August 4, 2026, will be critical for validating current growth trajectory and investor confidence.

Returns comparison

Trailing returns across standard periods

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY